Company intelligence / Profile preview

Zenshine Pharmaceuticals Co., Ltd.

Nanjing, Jiangsu, Chinaen.zenshine-pharma.com ↗

Ownership: Private
Development stage: NDA

Overview

Zenshine's lead drug candidate ZX-7101A (Seloxavir Marboxil) has completed Phase 3 trials and is currently in NDA stage in China for influenza treatment. ZX-4081 (PI3Kγ inhibitor) is in Phase I clinical trials in the US. ZX-101A (PI3Kδ/γ inhibitor) is in Phase I/IIa clinical trials in China and US for solid tumors and hematological malignancies. ZX-8177 (ENPP1 inhibitor) has received IND approval in China for advanced solid tumors.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

7 assets

Seloxavir marboxil

6 more assets in the full pipeline.

Partnerships

Jichuan Pharmaceutical (commercial strategic cooperation agreement as of August 2023)

Beyond the preview

Go deeper on Zenshine Pharmaceuticals Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zenshine Pharmaceuticals Co., Ltd..